Leland Stanford Junior University

Holden Terry Maecker

Dean W Felsher

Henrik Mei

Michael Duane Leipold

Srividya Swaminathan

Compositions and methods are provided for classification and treatment of MYC-driven cancers, i.e. causally dependent on MYC as a result of, over-expression of MYC, constitutive expression of MYC, chromosomal translocation resulting in overactive MYC, and the like. Specifically, the methods comprising determining the MYC status of the cancer, and in a cancer that is determined to be driven by MYC activation, administering a composition of an effective dose of one or both of activated natural killer (NK) cells and a type 1 interferon.

Profiling and treatment of MYC-associated cancers with NK cells and type 1 interferon

The present disclosure provides analyte-specific binding reagents conjugated with a platinum-containing moiety, e.g., cisplatin, and methods, compositions, and kits for their production and use in assays for analyte detection.

Growing community of inventors

Palo Alto, CA, United States of America

Holden Terry Maecker